Cohen Cynthia, Lohmann Christina M, Cotsonis George, Lawson Diane, Santoianni Robert
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Mod Pathol. 2003 Jun;16(6):574-83. doi: 10.1097/01.MP.0000073868.31297.B0.
Survivin is a novel inhibitor of apoptosis commonly detected in tissues during fetal development and in cancer, but not usually in normal tissues. Expression of this protein may be of prognostic significance and therapeutically relevant in many cancers. We assessed survivin expression in ovarian carcinoma, correlating results with expression of other anti-apoptotic (bcl-2, bcl-x, mutant p53) and pro-apoptotic (bax) markers, with prognostic parameters, and prognosis. Paraffin-embedded sections of 49 ovarian carcinoma were immunostained for survivin, bcl-2, bcl-x, bax, and p53. Expression was evaluated in nuclei and cytoplasm, as intensity (0-3+), and percentage of positive cells was scored on a four-tiered system with <10% as negative. Frequency of survivin, bcl-2, bcl-x, bax, and p53 was 73.5%, 36.7%, 93.9%, 77.6%, and 60.4%, respectively. There was significant correlation between nuclear survivin expression and grade (P =.0014), histologic type (P =.0376), and mutant p53 (P =.0414). Survivin expression did not correlate with bcl-2, bcl-x, or bax expression, stage, or overall or disease-free survival. The majority (74%) of ovarian carcinoma show survivin expression, which correlates with poor prognostic parameters (high grade, histologic type, p53 mutation) but not with survival. Therapeutic targeting of survivin in ovarian carcinoma is a future possibility.
生存素是一种新型凋亡抑制因子，常见于胎儿发育组织和癌症组织中，而在正常组织中通常不表达。该蛋白的表达在许多癌症中可能具有预后意义且与治疗相关。我们评估了卵巢癌中生存素的表达情况，并将结果与其他抗凋亡（bcl-2、bcl-x、突变型p53）和促凋亡（bax）标志物的表达、预后参数及预后进行关联分析。对49例卵巢癌石蜡包埋切片进行生存素、bcl-2、bcl-x、bax和p53的免疫染色。在细胞核和细胞质中评估表达情况，以强度（0 - 3+）表示，并在四级系统上对阳性细胞百分比进行评分，<10%为阴性。生存素、bcl-2、bcl-x、bax和p53的表达频率分别为73.5%、36.7%、93.9%、77.6%和60.4%。细胞核生存素表达与分级（P = 0.0014）、组织学类型（P = 0.0376）和突变型p53（P = 0.0414）之间存在显著相关性。生存素表达与bcl-2、bcl-x或bax表达、分期、总生存期或无病生存期均无相关性。大多数（74%）卵巢癌显示生存素表达，这与不良预后参数（高级别、组织学类型、p53突变）相关，但与生存期无关。在卵巢癌中靶向治疗生存素是未来的一种可能性。
